Clinical Application of Novel Panels for Early Precision Diagnosis and Relapse Prediction in High-risk Leukemia
NCT ID: NCT03297476
Last Updated: 2022-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2017-12-01
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia
NCT00003861
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
NCT03564470
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
NCT01687400
Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML
NCT00538876
Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
NCT02914977
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
high-risk group
Selected by "High-risk subtype detection panels"
High-risk subtype detection panels
The designed detection technology were used to identify the high-risk patients cohort.
non high-risk group
Selected by "High-risk subtype detection panels"
High-risk subtype detection panels
The designed detection technology were used to identify the high-risk patients cohort.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High-risk subtype detection panels
The designed detection technology were used to identify the high-risk patients cohort.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
14 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhongda Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ge Zheng
Director of Hematology Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZDYYGZ201708
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.